trending Market Intelligence /marketintelligence/en/news-insights/trending/t0alawhizcvyblst1vjdpw2 content esgSubNav
In This List

Karyopharm Therapeutics elects director

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Dealmaking slumps; rate hikes hammer gold; transaction banking revenues jump

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future


Karyopharm Therapeutics elects director

Newton, Mass.-based biotechnology company Karyopharm Therapeutics Inc. elected F. Carsten Thiel as a Class II director.

Thiel's term will expire at the company's 2021 annual meeting of stockholders.

Karyopharm's board increased the number of directors comprising the board to eight from seven and increased the number of Class II directors to two in connection with Thiel's appointment.